Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging

Academic Radiology

Volumn 7, Issue 10, 2000, Pages 800-811

  Li, William W ^a  

^a The Angiogenesis Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANGIOZYME; AVICINE; CILENGITIDE; CM 101; COMBRESATIN A4; CYCLOSPORIN; ENDOSTATIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; IM 862; IMC 1C11; IMC IC11; METHOTREXATE; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; PI 88; PRODRUG; REBIMASTAT; RECOMBINANT HUMAN VASCULOTROPIN MONOCLONAL ANTIBODY; SQUALAMINE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE;

ANGIOGENESIS; ARTICLE; CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG TARGETING; HUMAN; IMAGING; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0033775313     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(00)80629-7     Document Type: Article

References (139)

1. Lessons to be learned from clinical trials of angiogenesis modulators in ischemic diseases
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Starving the synovium: Angiogenesis and inflammation in rheumatoid arthritis
4. Factors controlling ocular angiogenesis
5. Angiogenesis in dermatology: Pathophysiology and clinical implications
6. Tumor angiogenesis: Therapeutic implications
7. The role of the vascular phase in solid tumor growth: A historical review
8. Mechanisms of angiogenesis
9. What is the evidence that tumors are angiogenesis dependent?
10. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
11. Clinical applications of research on angiogenesis
12. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a
13. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a
14. Bone marrow angiogenesis and progression in multiple myeloma
15. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
16. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
17. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
18. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
19. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
20. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis
21. Regulation of angiogenesis via vascular endothelial growth factor receptors
22. Angiogenesis in ischemic heart disease
23. Induction of angiogenesis during the transition from hyperplasia to neoplasia
24. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
25. Angiogenic factors as tumor markers
26. Basic fibroblast growth factor in the cerebrospinal fluid of children with brain tumors: Correlation with microvessel count in the tumor
27. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
28. Diagnostic value of serum VEGF in women with ovarian tumors
29. Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression
30. Angiogenesis in mice with chronic airway inflammation: Strain-dependent differences
31. Angiogenesis and inflammation in invasive carcinoma of the breast
32. Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis
33. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma
34. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma
35. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
36. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
37. Antiangiogenesis restricted tumor dormancy
38. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
39. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
40. Multiple forms of angiostatin induce apoptosis in endothelial cells
41. Endostatin induces endothelial cell apoptosis
42. Isolation of putative progenitor endothelial cells for angiogenesis
43. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor
44. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-g and migration of endothelial cells expressing Flt-1
45. Activation of mitogen-activated proteinase kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin
46. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
47. Control of apoptosis during angiogenesis by survivin expression in endothelial cells
48. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway
49. First steps of tumor-related angiogenesis
50. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
51. Intussusceptive angiogenesis: Its role in embryonic vascular network formation
52. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis
53. Genetic control of branching morphogenesis
54. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
55. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
56. Vascular attack as a therapeutic strategy for cancer
57. Migration of capillary endothelial cells is stimulated by tumor-derived factors
58. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulated VEGF-induced postnatal neovascularization
59. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
60. Definition of two angiogenic pathways by distinct alpha v integrins
61. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
62. Matrix metalloproteinases: Biologic activity and clinical implications
63. Complex role of matrix metalloproteinases in angiogenesis
64. Galectin-3 induces endothelial cell morphogenesis and angiogenesis
65. B1 integrin activation inhibits in vitro tube formation: Effects of cell migration, vacuole coalescence and lumen formation
66. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels
67. Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion of vacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells
68. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
69. Vasculogenic mimicry: How convincing, how novel and how significant?
70. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
71. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis
72. Vasculogenesis, angiogenesis and growth factors: Ephrins enter the fray at the border
73. Eph receptors and ephrins restrict cell intermingling and communication
74. Blood vessel formation: What is its molecular basis?
75. Blood vessel maturation: Vascular development comes of age
76. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells
77. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes
78. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
79. Successful treatment of an angiogenic disease
80. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
81. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470
82. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
83. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
84. The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo
85. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
86. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration
87. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and reduction of urokinase-type plasminogen activator
88. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse
89. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
90. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
91. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
92. Angiogenesis inhibition: A review
93. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
94. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
95. Integrin signaling
96. Death to a blood vessel, death to a tumor
97. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
98. Endothelial progenitor cells as putative targets for angiostatin
99. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
100. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression
101. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer)
102. TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-kappaB, nuclear factor-AT, and activation of protein-1 transcription factors
103. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
104. Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation
105. A systems approach to cancer therapy
106. Barriers to drug delivery in solid tumors
107. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
108. Delay in administration of CDDP until completion of AGM-1470 treatment enhances antimetastatic and antitumor effects
109. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
110. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
111. Clinical trials of angiogenesis-based therapies: Overview and new guiding principles
112. Tumor-associated angiogenesis: Mechanisms, clinical implications and therapeutic strategies
113. Vogelzang Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
114. Surrogate end points in clinical trials: Are we being misled?
115. Tumor angiogenesis: Past, present and the near future
116. Monitoring responses to antiangiogenic agents using noninvasive imaging tests
117. CT measurements of capillary permeability within nodal masses: A potential technique for assessing the activity of lymphoma
118. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: A review
119. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma
120. New hemodynamic approach to angiogenesis: Color and pulsed Doppler ultrasonography
121. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma
122. Clinical application of intratumoral blood flow study in patients with endometrial carcinoma
123. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade
124. Mammary carcinoma model: Correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density
125. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
126. Determining hypoxic fraction in a rat glioma by uptake of radiotabeled fluoromisonidazole
127. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
128. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
129. Cancer treatment by targeted drug delivery to tumor vasculature
130. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
131. Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells
132. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
133. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
134. Thermography: Its relation to pathologic characteristics, vascularity, proliferation rat, and survival in patients with invasive ductal carcinoma of the breast
135. Breast thermography is a noninvasive prognostic procedure that predicts tumor growth rate in breast cancer patients
136. Concurrent MRI and diffuse optimal tomography of breast after indocyanine green enhancement